When to Stop Bosentan for Liver Enzyme Elevations
Bosentan, used for pulmonary arterial hypertension, requires monthly liver function tests (ALT/AST) due to hepatotoxicity risk. Stop treatment immediately if ALT/AST exceed 3x upper limit of normal (ULN) and bilirubin is ≥2x ULN, or if ALT/AST >8x ULN regardless of bilirubin. For ALT/AST 3-8x ULN with normal bilirubin, discontinue and recheck tests within 48-72 hours.[1][2]
Bosentan Discontinuation Doses for Liver Issues
- ALT/AST >3x and ≤5x ULN: Reduce dose to 62.5 mg twice daily; monitor twice weekly. Resume full dose (125 mg or 250 mg twice daily) if levels normalize.
- ALT/AST >5x and ≤8x ULN: Stop drug; recheck in 48 hours. Do not restart without specialist consult if confirmed.
- Permanent discontinuation if symptomatic liver injury or levels do not decline.[1][2]
Handling Other Side Effects Like Anemia or Edema
For hemoglobin drop >15% or edema, do not stop immediately—reduce dose or monitor. Anemia often resolves without discontinuation; treat if severe. Stop only if life-threatening or per clinician judgment.[1]
Restarting Bosentan After Stopping
Do not restart if ALT/AST >8x ULN or jaundice occurs. For milder elevations, restart at low dose (62.5 mg twice daily) only after normalization and specialist approval. Monthly monitoring continues indefinitely.[1][2]
Patient Monitoring Timeline Post-Discontinuation
Recheck liver tests 2-3 days after stopping for elevations >3x ULN. If levels fall below 3x ULN, consider rechallenge after 2-4 weeks. Report symptoms like nausea, fatigue, or jaundice immediately.[1]
[1]: Bosentan Prescribing Information (Tracleer)
[2]: DrugPatentWatch.com - Bosentan Patents and Labeling